II. Indications
- HIV Infection (part of combination therapy)
III. Contraindications
- Severe hepatic Impairment (Child-Pugh Class C)
- Creatinine Clearance <30 ml/min
IV. Mechanism
V. Medications
- Bictegravir
- As of 2023, Bictegravir is only available in the U.S. in the combination agent Biktarvy
- Biktarvy Combination Agent (InSTI and 2 nRTI agents)
- Contents
- Bictegravir (BIC) 50 mg Biktarvy
- Emtricitabine (FTC) 200 mg
- Tenofovir Alafenamide (TAF) 25 mg
- Dosing
- Take one tablet orally daily with or without food
- Test for Hepatitis B before starting Biktarvy
- Indications
- Stable HIV RNA <50 copies/ml (>3 months) without treatment failures or resistance mutations
- Contraindications
- Creatinine Clearance <30 ml/min
- Drug Interactions
- Fewer Drug Interactions than Genoya and no Genetic Testing needed before use
- Avoid with high dose NSAIDS (Nephrotoxicity Risk)
- Avoid within 2 hours of Antacid salts (Mg, Ca, Al)
- Contents
VI. Drug Interactions: Bictegravir
- Reduced absorption with Antacid salts (Mg, Ca, Al)
- Take 2 hours before or after Bictegravir
- OAT2 and MATE1 Transport inhibition by Bictegravir
- Avoid Dofetilide (risk of toxic levels)
- Avoid drugs that reduce the serum concentrations and effectiveness of Bictegravir (metabolized by CYP3A4)
- Avoid Rifampin, Rifabutin, Rifapentine
- Avoid St Johns Wort
- Consider alternatives to specific antiepileptics
VII. Resources
VIII. References
- (2018) Presc Lett, New Drug: Biktarvy Resource #340611
Images: Related links to external sites (from Bing)
Related Studies
| bic (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| BICALUTAMIDE 50 MG TABLET | Generic | $0.26 each |
| biktarvy (on 12/7/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| BIKTARVY 50-200-25 MG TABLET | $115.81 each | |